Pulmatrix is a clinical stage biotechnology company developing a new class of inhaled therapies that harness the body’s natural host defenses and immune response in the airway to safely prevent and treat respiratory infections, reduce inflammation, and prevent acute exacerbations in patients with chronic inflammatory airway disease.


Date Type Amount Investors Valuation
08/01/11 Series B 14M Polaris Venture Partners, 5AM Ventures, Arch Venture Partners, Novartis Venture Fund Unknown